Nutriband Inc. cash flow statement
In fiscal 2026, Nutriband Inc.'s operations generated −$5.1m of cash; it spent $5,324 on capital projects, leaving free cash flow of −$5.1m.
Cash flow statement
| Fiscal year | 2019Jan 2019 | 2020Jan 2020 | 2021Jan 2021 | 2022Jan 2022 | 2023Jan 2023 | 2024Jan 2024 | 2025Jan 2025 | 2026Jan 2026 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,105 | −894 | −297 | −2,809 | −2,987 | −3,528 | −4,627 | −5,135 | −3,632 |
| Depreciation and amortisation | 37 | 72 | 160 | 309 | 330 | 288 | 285 | 194 | 146 |
| Stock-based pay | 1,764 | 253 | 2,005 | 365 | 732 | 500 | 1,409 | 2,634 | — |
| Capital spending | 4 | — | — | 82 | 79 | 52 | 92 | 5 | 0 |
| Free cash flow | −1,110 | — | — | −2,891 | −3,067 | −3,579 | −4,719 | −5,140 | −3,632 |
| Free cash flow after stock pay | −2,874 | — | — | −3,256 | −3,799 | −4,079 | −6,128 | −7,774 | — |
| Shares issued | 1,500 | — | 515 | 583 | — | — | 8,407 | 5,306 | — |
| Quarter | 2025 Q3Oct 2024 | 2025 Q4Jan 2025 | 2026 Q1Apr 2025 | 2026 Q2Jul 2025 | 2026 Q3Oct 2025 | 2026 Q4Jan 2026 | 2027 Q1Apr 2026 | 2027 Q2Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,010 | −1,239 | −1,337 | −1,313 | −1,752 | −732 | −563 | −585 |
| Depreciation and amortisation | 73 | 73 | 57 | 57 | 43 | 36 | 34 | 33 |
| Stock-based pay | 0 | 856 | — | — | — | 99 | 552 | — |
| Capital spending | 47 | 0 | 5 | 0 | 0 | 0 | — | 0 |
| Free cash flow | −1,057 | −1,239 | −1,342 | −1,313 | −1,752 | −732 | — | −585 |
| Free cash flow after stock pay | −1,057 | −2,095 | — | — | — | −830 | — | — |
| Shares issued | 0 | 7 | — | — | 0 | 0 | — | — |
Compare with peers
- Lipocine Inc. cash flow
- China SXT Pharmaceuticals, Inc. cash flow
- 60 Degrees Pharmaceuticals, Inc. cash flow
- Eyepoint, Inc. cash flow
- Scienture Holdings, Inc. cash flow
Head to head: LPCN vs NTRBNTRB vs SXTCNTRB vs SXTPEYPT vs NTRB
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies